Lp-PLA2 Activity and Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack
Stroke · 2026
DOI: 10.1161/strokeaha.125.052954 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Stroke, 2026. Verfasst von Jinxi Lin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J…. Hauptthemen laut MEDLINE: 1-Alkyl-2-acetylglycerophosphocholine Esterase, Aspirin, Clopidogrel, Dual Anti-Platelet Therapy. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
BACKGROUND: Lp-PLA2 (lipoprotein-associated phospholipase A2) is a sensitive biomarker of vascular inflammation and atherosclerosis. This study evaluated the influence of Lp-PLA2 activity on the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin among patients with minor stroke or transient ischemic attack carrying CYP2C19 loss-of-function alleles. METHODS: The CHANCE-2 trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events-II) randomized 6412 patients with minor stroke or transient ischemic attack carrying CYP2C19 loss-of-function alleles to receive ticagrelor-aspirin or clopidogrel-aspirin. This subgroup study included patients with available baseline Lp-PLA2 activity measurements, stratified by the median value of 188.4 nmol/min per milliliter. The primary efficacy and safety outcomes were stroke recurrence and severe or moderate bleeding events within 90 days. Associations between treatment and outcomes were assessed using multivariable Cox proportional hazards models, adjusting for a history of hyperlipidemia. RESULTS: A total of 5919 patients were included (mean age, 64.4 years; 33.9% female). Among patients with low Lp-PLA2 activity, ticagrelor-aspirin reduced the 90-day risk of recurrent stroke compared with clopidogrel-aspirin (5.4% versus 7.4%; adjusted hazard ratio, 0.72 [95% CI, 0.54–0.97]). In patients with high Lp-PLA2 activity, no significant difference was observed (6.9% versus 8.2%; adjusted hazard ratio, 0.84 [95% CI, 0.65–1.09]). The P value was 0.45 for the treatment × Lp-PLA2 activity interaction effect on stroke recurrence. The risk of bleeding associated with ticagrelor–aspirin did not differ across Lp-PLA2 activity levels. CONCLUSIONS: In patients with minor stroke or transient ischemic attack carrying CYP2C19 loss-of-function alleles, elevated Lp-PLA2 activity did not significantly modify the efficacy or safety of dual antiplatelet therapy. Further research is needed to clarify the potential role of Lp-PLA2 in guiding individualized treatment decisions. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04078737.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J.J., Y.J., Yilong Wang, X.Z., H.L., Z.L., Yongjun Wang).
- China National Clinical Research Center for Neurological Diseases, Beijing (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J.J., Y.J., Yilong Wang, X.Z., H.L., Z.L., Yongjun Wang).
- Tiantan Neuroimaging Center of Excellence, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.J.).
- Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences, Beijing, China (X.Z., Z.L., Yongjun Wang).
- Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China (Yongjun Wang).
ORCID-Profile: Hongyu Zhou, Yubo Wang, Aoming Jin, Xuewei Xie, Jing Jing, Yong Jiang, Yilong Wang, Xingquan Zhao, Zixiao Li, Yongjun Wang
Zitieren
APA
Lin, J., Zhou, H., Wang, Y., Jin, A., Li, S., Zhang, L., Meng, X., Xie, X., Jing, J., Jiang, Y., Wang, Y., Zhao, X., Li, H., Li, Z., Wang, Y., & CHANCE-2 Investigators (2026). Lp-PLA2 Activity and Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack. Stroke. https://doi.org/10.1161/strokeaha.125.052954
Vancouver
Lin J, Zhou H, Wang Y, Jin A, Li S, Zhang L, et al. Lp-PLA2 Activity and Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack. Stroke. 2026. doi:10.1161/strokeaha.125.052954
BibTeX
@article{Lin2026,
author = {Lin, Jinxi and Zhou, Hongyu and Wang, Yubo and Jin, Aoming and Li, Shangzhi and Zhang, Ling and Meng, Xia and Xie, Xuewei and Jing, Jing and Jiang, Yong and Wang, Yilong and Zhao, Xingquan and Li, Hao and Li, Zixiao and Wang, Yongjun and CHANCE-2 Investigators, CHANCE-2 Investigators},
title = {Lp-PLA2 Activity and Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack},
journal = {Stroke},
year = {2026},
doi = {10.1161/strokeaha.125.052954}
}
EUVIMED